Jonathan E. Brammer, MD, discusses the importance of achieving minimal residual disease negativity in relapsed/refractory acute lymphoblastic leukemia.
Jonathan E. Brammer, MD, assistant professor, internal medicine, The Ohio State University Comprehensive Cancer Center—–James, discusses the importance of achieving minimal residual disease (MRD) negativity in relapsed/refractory acute lymphoblastic leukemia (ALL).
MRD is an important predictor of outcomes in both B-cell ALL and T-cell ALL, says Brammer. The majority of patients who are MRD positive after induction chemotherapy will relapse.
The phase II BLAST study evaluated the bispecific T-cell engager blinatumomab (Blincyto). The drug received regulatory approval in 2018 for the treatment of adult and pediatric patients with MRD-positive B-cell precursor ALL. The study confirmed that blinatumomab is effective in eradicating MRD in patients who received at least 3 cycles of prior treatment. Notably, many of these patients were subsequently eligible to receive stem cell transplantation, concludes Brammer.